Trastuzumab
Title: Trastuzumab
CAS Registry Number: 180288-69-1
CAS Name: Anti-(human p185neu receptor) immunoglobulin G1 (human-mouse monoclonal rhuMab HER2 g1-chain) disulfide with human-mouse monoclonal rhuMab HER2 light chain, dimer
Additional Names: rhuMab HER2
Trademarks: Herceptin (Genentech)
Literature References: Humanized monoclonal antibody directed against the protein product of the HER2/neu oncogene which is homologous to the human epidermal growth factor receptor and is overexpressed by certain tumor cells. Constructed by inserting the antigen binding regions of murine monoclonal antibody 4D5 into the framework of a consensus human immunoglobulin G1. Prepn: R. M. Hudziak et al., WO 8906692; eidem, US 5677171 (1989, 1997 both to Genentech); P. Carter et al., Proc. Natl. Acad. Sci. USA 89, 4285 (1992). Analysis by capillary electrophoresis: G. Hunt et al., J. Chromatogr. A 744, 295 (1996). Clinical evaluation in combination with cisplatin in breast cancer: M. D. Pegram et al., J. Clin. Oncol. 16, 2659 (1998). Review of clinical efficacy: G. N. Hortobagyi, Semin. Oncol. 28, Suppl. 18, 43-47 (2001); of clinical safety and tolerability in breast cancer: S. Rueckert et al., Expert Opin. Biol. Ther. 5, 853-866 (2005).
Therap-Cat: Antineoplastic.
Keywords: Antineoplastic; Monoclonal Antibodies.

Others monographs:
NatamycinAntimony SulfateMaleuric AcidBismuth Potassium Iodide
CilazaprilElement 112Cuprous ChloridePhosphorus Pentachloride
Vanadium Pentoxide2-EthoxyethanolPhthalofyneTeriflunomide
Boron TrichlorideCiclopirox3-CareneCefquinome
©2016 DrugLead US FDA&EMEA